Charles River Laboratories International Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $743.1M | $751.0M | $747.9M | $665.1M | $619.9M | $528.9M | $517.6M | $443.9M |
| Operating Income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M | $432.7M | $351.2M | $331.4M |
| Operating Margin | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% |
| Interest Expense | — | — | $136.7M | $59.3M | $73.9M | $86.4M | $60.9M | $63.8M |
| Pretax Income | $-99.5M | $93.1M | $581.3M | $623.0M | $480.7M | $447.1M | $304.1M | $281.7M |
| Income Tax Expense | $42.7M | $67.8M | $100.9M | $130.4M | $81.9M | $81.8M | $50.0M | $54.5M |
| Net Income | $-144.3M | $22.2M | $474.6M | $486.2M | $391.0M | $364.3M | $252.0M | $226.4M |
| Net Margin | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 |
| Shares Outstanding (Basic) | 49.6M | 51.4M | 51.2M | 50.8M | 50.3M | 49.6M | 48.7M | 47.9M |
| Shares Outstanding (Diluted) | 49.6M | 51.6M | 51.5M | 51.3M | 51.4M | 50.6M | 49.7M | 49.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |